Dr. Jon Cousin

Jon focuses on developing and executing worldwide patent strategies for life sciences and pharmaceutical companies. He counsels clients on drug design, life cycle extension strategies, clinical trial inventions and Orange Book listing strategies. Notable patent portfolios Jon has worked on include Epidiolex, Copiktra, Farydak, Arikayce, Amrix, Lamictal and Evekeo ODT, as well as numerous candidates in clinical trials.

He has counselled clients in small molecule and peptide drug discovery programs, polymorphs, pharmaceutical formulations, 505(b)(2) strategies, natural products, clinical trial inventions, companion diagnostics, biomaterials, biotechnologies and manufacturing processes.

Jon has significant experience conducting patentability, invalidity, freedom-to-operate and noninfringement analyses, along with conducting due diligence for early-, mid- and late-stage fundraisings, public offerings, acquisitions and dispositions.  

Speaking engagements

• Co-presenter, “Life Sciences Litigation: Clinical Trials and Tribulations – Prosecution and Litigation Implications of Clinical Trial IP and Prior Art,” Cooley Rx series, May 2025
• Co-presenter, “Clinical Trials and Tribulations: Prosecution and Litigation Implications of Clinical Trial IP and Prior Art,” Consero IP Forum for Life Sciences, December 2024
• Co-presenter, “505(b)(2) Applications and Beyond: Prosecution and Litigation Strategies for Filing and Defending Against 505(b)(2) NDAs,” Cooley Rx series, October 2024
• Co-presenter, “Planning for the Future: Aligning Prosecution and Litigation Strategies,” Cooley Rx series, September 2024